Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression

Purwanto, Ibnu and Leo, Benedreky and Hutajulu, Susanna Hilda and Kurnianda, Johan and Taroeno-Hariadi, Kartika Widayati and Hardianti, Mardiah Suci and Satiti, Amanda Dania and Dwianingsih, Ery Kus and Heriyanto, Didik Setyo and Widodo, Irianiwati and Aryandono, Teguh (2023) Prognostic Value of Vimentin in Triple Negative Breast Cancer Patients Depends on Chemotherapy Regimen and p53 Mutant Expression. Breast Cancer: Targets and Therapy, 15. pp. 515-524. ISSN 11791314

[thumbnail of 485_Ibnu Purwanto.pdf] Text
485_Ibnu Purwanto.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.

Download (2MB) | Request a copy

Abstract

Purpose: To determine the prognostic value of vimentin in triple negative breast cancer (TNBC) patients, specifically in relation to chemotherapy regimen and p53 mutant expression. Patient and Methods: We retrospectively analyzed the association of pre-treatment tumor expression of vimentin with 48-month overall survival (OS) of 72 all stages TNBC patients diagnosed between 2014 and 2018 in relation to chemotherapy regimen and expression of p53 mutant. Vimentin and p53 mutant expressions were examined using immunohistochemistry. Analysis was conducted on all patients collectively, then repeated on two cohorts divided according to the chemotherapy regimen. Sub-analysis was performed to determine the effect of p53 mutant expression on the prognostic value of vimentin. Results: Vimentin was expressed in 43.1 of patients and was not associated with clinicopathologic characteristics. Vimentin was associated with improved 48-month OS in all patients in univariate analysis but not significant in multivariate analysis. When analyzed according to chemotherapy regimen, vimentin was independently associated with improved 48-month OS in patients receiving non-platinum-based chemotherapy (80 vs 15.8; HR: 0.17, 95 CI: 0.05–0.58, p: 0.005). Other independent prognostic factors include T (HR: 6.18, 95 CI: 1.38–27.7, p: 0.017) and M (HR: 5.64, 95 CI: 1.2–26.33, p: 0.028). On subanalysis, vimentin was significantly associated with improved 48-month OS in patients expressing p53 mutant (69.2 vs 22.2, p: 0.006) but was not significant in patients not expressing p53 mutant. Conclusion: Vimentin expression was independently associated with improved 48-month OS in TNBC patients treated with non– platinum–based chemotherapy. Expression of p53 mutant significantly affected the prognostic value of vimentin. © 2023 Purwanto et al.

Item Type: Article
Additional Information: Library Dosen
Uncontrolled Keywords: platinum; protein p53; vimentin; adult; Article; body mass; cancer chemotherapy; cancer prognosis; cancer staging; cohort analysis; ECOG Performance Status; female; follow up; gene expression; hazard ratio; human; human tissue; immunohistochemistry; Kaplan Meier method; major clinical study; observational study; overall survival; protein expression; retrospective study; triple negative breast cancer; tumor volume
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine, Public Health and Nursing > Public Health and Nutrition
Depositing User: Ngesti Gandini
Date Deposited: 19 Jun 2024 06:36
Last Modified: 19 Jun 2024 06:36
URI: https://ir.lib.ugm.ac.id/id/eprint/2550

Actions (login required)

View Item
View Item